Cognitive Model of Eating Disorders

2001 ◽  
Vol 15 (4) ◽  
pp. 331-340 ◽  
Author(s):  
Wayne A. Bowers

Cognitive behavior Therapy (CBT) has been shown to be more effective or at least as effective as other psychotherapies in the treatment of bulimia nervosa with change being maintained 5 years after the end of treatment. Additionally, empirical studies demonstrate that CBT is superior to antidepressant medications in the treatment of bulimia nervosa. Less is known about CBT for anorexia nervosa but initial research suggests it may play a prominent role in treatment. CBT can influence changes in negative thoughts and schemas in anorexia nervosa as well as influence core eating disorder psychopathology and alter depressed mood. CBT may prevent relapse in the treatment of anorexia nervosa. More research is needed on the use of CBT in anorexia nervosa.

2018 ◽  
Vol 51 (9) ◽  
pp. 1098-1102 ◽  
Author(s):  
Lazaro V. Zayas ◽  
Shirley B. Wang ◽  
Kathryn Coniglio ◽  
Kendra Becker ◽  
Helen B. Murray ◽  
...  

2004 ◽  
Vol 34 (8) ◽  
pp. 1395-1406 ◽  
Author(s):  
MANFRED M. FICHTER ◽  
NORBERT QUADFLIEG

Background. Since little is known about the long-term course and outcome of bulimia nervosa, the authors designed a 12-year prospective longitudinal study with five cross-sectional assessments based on a large sample of consecutively treated females with bulimia nervosa (purging type) (BN-P).Method. One hundred and ninety-six females with BN-P were assessed (1) at the beginning of treatment, (2) at the end of treatment, (3) at 2-year follow-up, (4) at 6-year follow-up, and (5) at 12-year follow-up. In self-ratings as well as expert ratings based on interviews we assessed specific eating-disorder and general psychopathology.Results. The general pattern of results over time showed substantial improvement during treatment, slight (in most cases non-significant) decline during the first two years after the end of treatment, and further improvement and stabilization until 12-year follow-up. At that point the majority of patients (70·1%) showed no major DSM-IV eating disorder, 13·2% had eating disorders not otherwise specified, 10·1% had BN-P and 2% had died. Very few had undergone transition to anorexia nervosa or binge-eating disorders. Logistic regression analyses showed that psychiatric co-morbidity was the best and most stable predictor for eating-disorder outcome at 2, 6 and 12 years.Conclusions. Course and outcome of BN-P was generally more favourable than for anorexia nervosa.


Author(s):  
Susan McElroy ◽  
Anna I. Guerdjikova ◽  
Nicole Mori ◽  
Paul E. Keck

This chapter addresses the pharmacotherapy of the eating disorders (EDs). Many persons with EDs receive pharmacotherapy, but pharmacotherapy research for EDs has lagged behind that for other major mental disorders. This chapter first provides a brief rationale for using medications in the treatment of EDs. It then reviews the data supporting the effectiveness of specific medications or medication classes in treating patients with anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), and other potentially important EDs, such as night eating syndrome (NES). It concludes by summarizing these data and suggesting future areas for research in the pharmacotherapy of EDs.


Author(s):  
Pamela Keel

The epidemiology of eating disorders holds important clues for understanding factors that may contribute to their etiology. In addition, epidemiological findings speak to the public health significance of these deleterious syndromes. Information on course and outcome are important for clinicians to understand the prognosis associated with different disorders of eating and for treatment planning. This chapter reviews information on the epidemiology and course of anorexia nervosa, bulimia nervosa, and two forms of eating disorder not otherwise specified, binge eating disorder and purging disorder.


Author(s):  
Susan L. McElroy ◽  
Anna I. Guerdjikova ◽  
Anne M. O’Melia ◽  
Nicole Mori ◽  
Paul E. Keck

Many persons with eating disorders (EDs) receive pharmacotherapy, but pharmacotherapy research for EDs has lagged behind that for other major mental disorders. In this chapter, we first provide a brief rationale for using medications in the treatment of EDs. We then review the data supporting the effectiveness of specific medications or medication classes in treating patients with anorexia nervosa (AN), bulimia nervosa, binge eating disorder (BED), and other potentially important EDs, such as night eating syndrome (NES) and sleep-related eating disorder (SRED). We conclude by summarizing these data and suggesting future areas for research in the pharmacotherapy of EDs.


Author(s):  
Christopher Hübel ◽  
Mohamed Abdulkadir ◽  
Moritz Herle ◽  
Ruth J. F. Loos ◽  
Gerome Breen ◽  
...  

Author(s):  
Janet A. Lydecker ◽  
Lauren Simpson ◽  
Shannon R. Smith ◽  
Marney A. White ◽  
Carlos M. Grilo

Sign in / Sign up

Export Citation Format

Share Document